Texas Mounjaro Lawsuit Attorneys

Thyroid tumors have become primary focuses in many Mounjaro lawsuits. Patients filing a Mounjaro lawsuit allege that Eli Lilly’s Mounjaro failed to adequately warn consumers about the potential side effects of cancer linked to GLP-1 receptor agonists. Research linking GLP-1 drugs to thyroid cancer includes a study in Diabetes Care showing that patients treated for 1-3 years faced nearly double the chances of being diagnosed with medullary thyroid cancer. PubMed Central found similar links to GLP-1 drugs and thyroid cancer. If you developed thyroid cancer after taking Mounjaro, a Texas Mounjaro attorney can help you pursue legal action against negligent drug manufacturers and seek compensation on your behalf.

Another potential complication of GLP-1 medications is pancreatitis. Patients allege the diabetes drug causes inflammation. PubMed Central identified serious health issues related to acute pancreatitis among patients using glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 receptor agonists, and DPP-4 inhibitors. A New England Journal of Medicine controlled trial reported pancreatitis cases in those receiving GLP-1 receptor agonist treatments. Such links are used in the legal process to demonstrate that Eli Lilly didn’t provide adequate warnings to patients and healthcare providers about links to life-threatening pancreatitis. If you suffered pancreatitis after taking Mounjaro, call a Texas Mounjaro attorney to determine if you qualify to file a Mounjaro lawsuit.

Delayed gastric emptying, often called gastroparesis or stomach paralysis, is a slowed digestive system process involving GLP-1 drugs, like Mounjaro. Patients allege that Eli Lilly and Company failed to provide adequate warnings that their stomachs could stop moving food. The Food and Drug Administration acknowledged the increased risk of gastroparesis in semaglutide drugs. Following this, the Ozempic and Wegovy warning labels were updated to include intestinal blockage. Media coverage, including CBS News, has highlighted how patients are suing over alleged side effects of weight-loss drugs, including digestive issues and stomach paralysis.

So, the federal multidistrict litigation focuses on stomach paralysis (gastroparesis) claims. Users have reported gastroparesis/stomach paralysis, a slowing of the digestive system after taking Mounjaro. Disputes hinge on diagnosing gastroparesis. The Judicial Panel on Multidistrict Litigation (MDL) is hearing arguments over whether stomach paralysis symptoms are sufficient or whether delayed gastric emptying tests are needed. Stomach paralysis/gastroparesis claims assert that Mounjaro manufacturer Eli Lilly failed to warn consumers about the potential risks of stomach paralysis. According to Healthline, “stomach paralysis… is a documented side effect of taking GLP‑1… drugs like Mounjaro and Ozempic”.

If you’ve suffered severe stomach paralysis (gastroparesis), contact a Texas Mounjaro lawyer for a free case review.

Intestinal obstruction is one of the severe gastrointestinal problems alleged in lawsuits related to GLP-1 drugs like Mounjaro. Intestinal blockage occurs when food or other contents can’t pass through the intestines. This leads to severe vomiting and pain. Doctors classify this gastrointestinal condition by the type of intestinal blockage. Medical records in intestinal blockage cases describe large and small intestine obstruction and paralytic ileus (intestines stop without a physical intestinal blockage).

The effectiveness of GLP-1 drugs like Mounjaro for regulating blood sugar relies on slowing the digestive system. This triggers stomach paralysis or intestinal obstruction, leading to many patients seeking emergency treatment, requiring surgery, and being diagnosed with digestive issues that weren’t on FDA warning labels.

If you had intestinal obstruction after taking Mounjaro, contact a Texas Mounjaro lawyer to determine if you’re eligible to file a Mounjaro lawsuit.

Mounjaro lawsuits highlight dehydration leading to acute kidney injury. These serious conditions often require hospital stays after prolonged vomiting and diarrhea cause significant fluid loss. The Mounjaro FDA label includes an increased risk of kidney-related side effects. It cites reports of kidney failure linked to GLP-1 drugs.

However, the FDA-approved warning label doesn’t include any safety risks associated with becoming dehydrated. Eli Lilly downplayed how often such severe side effects occur and progress to renal problems. Plaintiffs’ lawyers in the Mounjaro multidistrict litigation frame this as a failure-to-warn gap. The pharmaceutical company maintains that labeling is sufficient by linking gastrointestinal issues to potential risks of kidney complications. Our Texas Mounjaro lawyer team argues that Eli Lilly’s Mounjaro emphasized the rarity of acute kidney injuries while minimizing the cause.

If you sustained kidney damage, contact a Texas Mounjaro lawsuit attorney for a free consultation today.

Gallbladder disease and gallstones are other medical conditions linked to GLP-1. PubMed reported that GLP-1 receptor agonists were linked to an increased risk of biliary and gallbladder diseases. Researchers stated this increased when used as weight loss drugs, rather than for diabetes management. Frontiers in Endocrinology likewise reported an increased potential risk of gallbladder/biliary disease versus controls. Additionally, clinical studies published in the New England Journal of Medicine reported cases of cholecystitis associated with Mounjaro use.

According to Eli Lilly’s own data, 0.6% developed cholelithiasis and cholecystitis, while non-users were unaffected. So, Eli Lilly and the Food and Drug Administration knew about these health complications.

Clinical trials and studies published show that those taking Mounjaro developed gallbladder disease and gallstones, yet Eli Lilly neglected to warn users. This strengthens failure-to-warn claims. If you or a loved one suffered gallbladder complications after taking Mounjaro, contact a Texas Mounjaro lawsuit attorney for a free consultation.

The FDA label shows an increased health risk for diabetic retinopathy issues. This states the medical condition could worsen with Mounjaro tirzepatide drugs. However, Mounjaro manufacturer Eli Lilly didn’t adequately warn patients about non-arteritic anterior ischemic optic neuropathy (NAION) or other serious conditions. Research on GLP-1 drugs has increasingly pointed to a link. JAMA Ophthalmology found that patients prescribed semaglutide drugs had a higher incidence of NAION compared to non-GLP-1 users. More recently, a JAMA Network Open report suggested that tirzepatide may carry a similar health risk of vision loss. More research has fueled more lawsuits claiming that Eli Lilly and Company failed to warn consumers about vision loss.

If you were diagnosed with vision loss after taking Mounjaro, contact a Texas Mounjaro lawyer for a free case review.

Blood clot complications, including pulmonary embolism and deep vein thrombosis, have been cited in the class action lawsuit against Eli Lilly. BMJ Case Reports link pulmonary embolisms to Mounjaro use. Additionally, other resources suggest long-term GLP-1 receptor agonist treatment elevates the risk of deep vein thrombosis. Eli Lilly’s Mounjaro had no warning labels related to blood clots or secondary health complications.

If you suffered a blood clot, pulmonary embolism, or DVT after taking Mounjaro, a Texas Mounjaro lawsuit attorney from our law firm can help you take legal action and seek compensation for medical expenses, lost wages, and other costs related to the adverse effects of diabetes or weight loss medications.

The Mounjaro lawsuits claim severe gastrointestinal events. Claims related to serious gastrointestinal issues include severe vomiting, diarrhea, and nausea that led to extended hospital stays. These serious gastrointestinal side effects are a central focus of the Mounjaro class action lawsuit. Plaintiffs allege Eli Lilly failed to adequately warn consumers about the safety risks and severity of gastrointestinal problems. Over 1,800 plaintiffs have filed a Mounjaro lawsuit, with a growing number of victims coming forward to file lawsuits. The consolidated litigation includes Mounjaro lawsuits and cases for other weight loss drugs and diabetes drugs, like Ozempic and Wegovy.

If you’ve suffered severe gastrointestinal events or were diagnosed with a gastrointestinal condition, speak to a Texas Mounjaro lawsuit attorney for a free consultation.

Class action lawsuit plaintiffs have also alleged experiencing other gastrointestinal issues. While the first status conference focused on stomach paralysis or gastroparesis, intestinal obstruction, and pancreatitis, similar lawsuits describe persistent reflux and stomach burning as other serious gastrointestinal issues. Clinical studies support such complaints. WebMD shows higher rates of dyspepsia and reflux symptoms. Additionally, a safety study published documented treatment-emergent gastrointestinal problems, like reflux and heartburn, from GLP-1 medications.

If you experienced this or other serious side effects, contact a Texas Mounjaro attorney to discuss the legal process of filing a Mounjaro lawsuit.

Mounjaro lawsuits allege that weight loss leading to malnutrition was foreseeable. Plaintiffs accuse pharmaceutical companies, Novo Nordisk and Eli Lilly, of marketing diabetes drugs for off-label use as weight loss medications. Then, Mounjaro manufacturer Eli Lilly got FDA approval for sister medication, Zepbound, which has the same active ingredient, but is FDA-approved as a weight loss drug.

Mounjaro lawsuits claim Eli Lilly knew Mounjaro’s active ingredient would be used to help lose weight, but failed to warn users. The FDA-approved label mentions serious gastrointestinal issues but doesn’t identify malnutrition. Researchers have already proven the link between Mounjaro tirzepatide and concerning weight loss. BMJ experts expressed that patients treated with semaglutide drugs, whether as diabetes drugs or weight loss drugs, don’t consume enough calories.

This fuels allegations that the pharmaceutical companies failed to adequately warn patients. Plaintiffs argue that off-label prescriptions were predictable because Novo Nordisk and Eli Lilly marketed them to be.

If you or a loved one suffered from weight loss leading to malnutrition or other health complications after taking Mounjaro, you may be eligible to file a Mounjaro lawsuit. Our Texas Mounjaro lawyers are reviewing Mounjaro cases and can explain your legal options.

Experts have linked pulmonary aspiration as a health risk for GLP-1 drugs, like Mounjaro, Ozempic, and Wegovy. Because these diabetes and weight loss medications slow digestion, food remains in the stomach longer. In stomach paralysis cases, the stomach stops moving food entirely.

The American Society of Anesthesiologists warned users that GLP-1 receptor agonists may cause aspiration. They recommended that patients stop taking GLP-1 drugs before surgery. The Food and Drug Administration then included that ‘food remaining in the stomach could lead to pulmonary aspiration under general anesthesia’ on the label.

If you or a loved one suffered pulmonary aspiration or other injuries caused by Mounjaro or other weight loss drugs, contact a Texas Mounjaro lawsuit attorney. You may be eligible to seek compensation and justice for medical bills, lost wages, and other losses.